A genome-wide association study of anorexia nervosa suggests a risk locus implicated in dysregulated leptin signaling

Dong Li1, Xiao Chang1, John J. Connolly1, Lifeng Tian1, Yichuan Liu1, Elizabeth J. Bhoj1, Nora Robinson1, Debra Abrams1, Yun R. Li2, Jonathan P. Bradfield1, Cecilia E. Kim1, Jin Li1, Fengxiang Wang1, James Snyder1, Maria Lemma1, Cuiping Hou1, Zhi Wei1, Yiran Guo1, Haijun Qiu1, Frank D. Mentch1, Kelly A. Thomas1, Rosetta M. Chiavacci1, Roger Cone2,5, Bingshan Li2, Patrick A. Sleiman1, Eating Disorders Working Group of the Psychiatric Genomics Consortium, Price Foundation Collaborative Group & Hakon Hakonarson1,3,4

We conducted a genome-wide association study (GWAS) of anorexia nervosa (AN) using a stringently defined phenotype. Analysis of phenotypic variability led to the identification of a specific genetic risk factor that approached genome-wide significance (rs929626 in EBF1 (Early B-Cell Factor 1); \( P = 2.04 \times 10^{-7}; \) OR = 0.7; 95% confidence interval (CI) = 0.61–0.8) with independent replication (\( P = 0.04 \)), suggesting a variant-mediated dysregulation of leptin signaling may play a role in AN. Multiple SNPs in LD with the variant support the nominal association. This demonstrates that although the clinical and etiologic heterogeneity of AN is universally recognized, further careful sub-typing of cases may provide more precise genomic signals. In this study, through a refinement of the phenotype spectrum of AN, we present a replicable GWAS signal that is nominally associated with AN, highlighting a potentially important candidate locus for further investigation.

Anorexia nervosa (AN) is a complex and often chronic eating disorder characterized by inability to maintain a normal healthy body weight and a persistent fear of weight gain, resulting in extreme emaciation and even death in some cases1. Previous genetic and epidemiological studies have indicated a multifactorial etiology, where both genetic and environmental factors contribute to disease risk2–7.

As sample sizes have increased, genome-wide association studies (GWASs) of AN have begun to identify risk variants8–10. To further elucidate the genetic architecture of AN, we performed a GWAS using data from our previously published study8 consisting of 1,033 AN cases by excluding 212 patients with AN who experienced diagnostic crossover during the course of their illness. Specifically, we excluded patients who migrated from or to binge-eating disorder (BED) or bulimia nervosa (BN) as assessed with the Structured Interview for Anorexic and Bulimic Disorders11. Although a previous study indicated women with BN were rarely to cross over to AN12, we observed ~43% of AN/BN crossover cases falls into this category in our cohort, suggestive of a confounding factor. We hypothesized that this reduction in phenotypic heterogeneity, despite the fact that AN and BN may share some genetic risk factors13, would enhance gene discovery.
Results

Our discovery cohort included a total of 692 female AN cases of non-Hispanic European (NHE) descent. Cases were included if they were diagnosed with restricting type and binge eating/purging type of AN as defined by DSM-IV. Both types are characterized by below-normal weight and restricted food intake. Individuals diagnosed as restricting type do not experience binge-eating episodes and do not engage in purging, such as vomiting or use of laxatives. Standard quality controls measures were applied, specifically, excluding potential cryptic relatedness and checking for population stratification (details described elsewhere). The average age of onset of the case subjects was 16.3 years with a standard deviation (SD) of 3 years (Interquartile Range; IQR = 16 (14–18)). The control group included 3,570 female matched healthy adolescents of NHE ancestry that had an average age of 18.3 years at the time of data analysis (SD = 5.7; IQR = 19 (13–23)) (Supplementary Table 1). Associations were assessed with 507,999 SNPs genotyped on either Illumina HumanHap550 or Human610-Quad BeadChips in an additive model using logistic regression analyses with principal components adjustment, based on the principal component analysis of cases and controls (Supplementary Figure 1), resulting in significantly low level of genomic control inflation factor of 1.03 (Supplementary Figure 2). The analysis yielded one SNP (rs929626) with a $P$ value of $2.04 \times 10^{-2}$ and 4 other SNPs with marginally larger $P$ values that are in strong linkage disequilibrium ($r^2 > 0.8$); these SNPs were selected for further analysis (Supplementary Figure 3; Supplementary Table 2).

Using imputation analysis based on data from the 1000 Genomes Project (Phase I integrated variant set, v2, March 2012), we subsequently tested associations with SNPs (imputed info > 0.5, minor allele frequency (MAF) > 0.05) located in a 200-kb window centered on the SNP rs929626. We observed association with a series of markers around this region, of which 34 SNPs supported suggestive associations ($P < 1.0 \times 10^{-3}$) with both imputed and genotyped SNPs, which were in high LD with AN (Fig 1; Supplementary Table 3). This suggests that the single markers demonstrated nominal association in the GWAS and nominal association in the imputation analysis.

We further explored this finding using the meta-analysis results from 15 previously reported AN cohorts. Interestingly, two SNPs were also nominally significant (rs929626 with $P = 0.037$ and rs17543752 with $P = 0.05$) in the same direction as in the GWAS (Table 1). Meta-analysis results in a $P$ value of $1.52 \times 10^{-7}$.

We next used the ENCODE project data to predict possible functional effect of the SNPs identified in this study. The top SNP, rs929626, and other significant markers located in the 6th intron of the $EBF1$ gene (Early B-Cell Factor 1), as well as two SNPs (rs113252656 and rs1081071) flanking the top SNP rs929626 at $r^2 > 0.5$ function as binding sites for EBF1 itself (HaploReg v4.1; ref. 15). This suggests that these genetic variants may modulate the expression of $EBF1$. Indeed, we observed a positive correlation with the rs929626 C allele carriers compared with TT homozygotes on the $EBF1$ expression level in nine independent subjects (the FPKM value for TT homozygotes (3 subjects) versus C allele carriers (6 individuals) is 5.0 versus 6.4) with both whole genome sequencing data of blood and corresponding RNA-Seq data of heart right ventricle selected from the Pediatric Cardiac Genomics Consortium cohort (dbGaP Study Accession: phs000571.v3.p2). By using the Genotype-Tissue Expression Portal database (http://www.gtexportal.org), we also observed nominally significant expression quantitative trait loci (eQTLs) association ($P = 0.0024$, tested in 97 samples) in the putamen for rs929626 in the same direction. A few comorbid psychiatric disorders have been linked with the function of the putamen, such as anxiety, obsessive-compulsive disorder and attention deficit-hyperactivity disorder. Taken together, these suggest the minor allele C carriers have relatively higher $EBF1$ expression.

Discussion

$EBF1$ encodes a transcription factor that originally thought to function as necessary for the development of the immune system, but it has since been shown to regulate the development of both osteoblast and adipocyte lineages. Two $EBF1$ variants, rs11953630-T and rs9313772-T, showed significant association at genome-wide level ($P < 5 \times 10^{-8}$) in a study testing blood pressure in European whites. In addition, rs17056278-C was also identified as a metabolic risk allele, interacting with psychosocial stress to contribute to increased hip circumference ($P = 3 \times 10^{-4}$). However none of these is in LD with any markers in our identified locus. In animal studies, $Ebf1$−/− mice showed increased adipose tissue within marrow, whereas peripheral white adipose tissue was severely reduced. Circulating levels of leptin, a hormone released by adipocytes and one of the major players in food intake regulation, were also decreased in $Ebf1$−/− mice compared with controls. This concurs with the reported generalized loss of accumulation of subcutaneous and visceral adipose accompanied by significant increases in yellow marrow in AN patients. Also notable is the finding that circulating levels of leptin are very low in AN patients and a decline in levels of circulating leptin can lead to changes in brain activity in areas involved in regulatory, emotional, and cognitive control of appetite.

Understanding the genetics of AN is currently a major within-field initiative, in parallel to other neuropsychiatric/neurodevelopmental disorders such as schizophrenia, bipolar disorder, and autism spectrum disorders. Although the clinical and etiologic heterogeneity is universally recognized, in practice, many studies still failed to account for sample heterogeneity. In this study, by focusing on individuals with AN who have not crossed over to other eating disorder presentations, we have identified a marginally replicating GWAS signal that approached genome-wide significance.

One limitation of our study is that all participants may not yet have experienced the full course of their eating disorder (The average duration of follow-up was 8.6 years with a SD of 7.0 years in the discovery cohort, while the average crossover time was 2.8 years with a SD of 2.6 years for the excluded AN patients), and a portion of the sample may develop BN or BED at later stages of illness. This would represent a conservative bias and underscores the importance of further investigation of this locus in the future focusing on individuals with lifetime AN who have never crossed over to other eating disorder presentations.

Methods

Discovery data set and quality control. We conducted a GWAS using data from our previously published study consisting of 1,033 AN cases by excluding 212 patients with AN who experienced diagnostic...
crossover during the course of their illness (i.e. migrated from or to binge-eating disorder (BED) or bulimia nervosa (BN) as assessed with the Structured Interview for Anorexic and Bulimic Disorders) plus 100 patients without such information. A total of 692 female AN cases and 3,570 female matched controls that were carefully selected from Center for Applied Genomics (CAG) database were included in the analysis after Standard quality controls, namely, excluding potential cryptic relatedness and checking for population stratification by using the PLINK software version 1.90a. The Research Ethics Board of CHOP and other participating centers approved the study. Informed consent was obtained from all adult participants and from a parent or legal guardian in the case of children and all work followed was in accordance with an IRB-approved protocol.

### Association tests

For the genome-wide association analysis for SNPs, we utilized the PLINK software version 1.90a through Cochran–Armitage trend test.

### Expression studies

The extended locus around associated SNP was then defined by identification of all SNPs showing $r^2 > 0.5$. Linkage disequilibrium (LD) was defined with the HaploReg v4.1 (ref. 15) based on Phase I of the 1000 Genomes project. Variants showing evidence of LD with associated AN variants were explored for impact on gene function via regulatory function (including eQTLs) by HaploReg v4.1, which both collate data from the Encyclopedia of DNA Elements (ENCODE) and the Genotype-Tissue Expression Portal database for eQTLs analysis.

### References


Acknowledgements
We gratefully thank all the patients and their families who were enrolled in this study, as well as all the control subjects who donated blood samples to The Children's Hospital of Philadelphia (CHOP) for genetic studies. Ding Li was funded in part by 2012–2015 Davis Foundation Postdoctoral Fellowship Program in Eating Disorders Research Award. Bingshan Li was partially supported by Klarmann Family Foundation for eating disorders. All genome-wide genotyping for controls was funded by an Institute Development Award to Center for Applied Genomics from CHOP. We thank the Eating Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED) for providing summary results data for the replication analysis.

Author Contributions
D.L. and H.H. were leading contributions in the design, analysis and writing; D.L., X.C., Y.L., J.P.B. and P.S contributed to data analysis. J.J.C., I.T., N.R., D.A., Y.R.L. contributed samples and phenotypes. C.E.K., J.L., F.W., J.S., M.L., C.H., Z.W., Y.G., H.Q., F.M., K.T., R.C., B.L., and R.C. provided assistance with samples and data processing. Eating Disorders Working Group of the Psychiatric Genomics Consortium and Price Foundation Collaborative Group provided data for the replication and helped with the discussion; D.L. drafted the manuscript. D.L., J.J.C., E.J.B. and H.H. revised the manuscript. All authors approved final version of manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-01674-8.

Competing Interests: The authors declare that they have no competing interests.
Consortia
Eating Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED)

Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland
Department of Child and Adolescent Psychiatry, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
Hjelt Institute, University of Helsinki, Helsinki, Finland
Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland
Department of Mental Health and Substance Abuse Services, National Institute for Health and Welfare, Helsinki, Finland
Department of Adolescent Psychiatry, Helsinki University Central Hospital, Helsinki, Finland
Center for Eating Disorders Ursula, Leiden, The Netherlands
Leiden University Medical Centre, Department of Psychiatry, Leiden, The Netherlands
Leiden University Medical Centre, Molecular Epidemiology Section (Department of Medical Statistics), Leiden, The Netherlands
Department of Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA, USA
Department of Genetics, Environment and Mental Health, Norwegian Institute of Public Health, Oslo, Norway
Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Department of Psychiatry, University of Naples SUN, Naples, Italy
Chair of Psychiatry, University of Salerno, Salerno, Italy
Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada
Department of Psychiatry, University of Toronto, Toronto, Canada
Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
Department of Molecular and Experimental Medicine and The Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, CA, USA
Department of Psychosomatic Research, National Institute of Mental Health, NCPN, Tokyo, Japan
Department of Molecular Life Sciences, Tokai University School of Medicine, Kanagawa, Japan
Estonian Genome Center, University of Tartu, Tartu, Estonia
Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
Seattle University College of Nursing, Seattle, WA, USA
Kartini Clinic, Portland, OR, USA
Centre de Psychiatrie et Neurosciences – Inserm U894, Paris, France
Department of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King’s College London, London, UK
UCL Genetics Institute, Department of Genetics, Evolution and Environment, University College London, London, UK
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Clinics RWTH Aachen, Aachen, Germany
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Charité, Berlin, Germany
Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany
Department of Psychosomatic Medicine and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Würzburg, Würzburg, Germany
Department of Child and Adolescent Psychiatry, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
Massachusetts General Hospital/Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, Psychiatric Neuroimaging Research Program, Charlestown, MA, USA
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Clinics RWTH Aachen, Aachen, Germany
Departments of Psychosocial and Internal Medicine, Heidelberg University, Heidelberg, Germany
Parklandklinik, Bad Wildungen, Germany
Institute for Medical Informatics, Biometry and Epidemiology, Universitätssklinikum Essen, University of Duisburg-Essen, Essen, Germany
Department of Internal Medicine VI, Psychosomatic Medicine and Psychotherapy, University Medical Hospital Tübingen, Tübingen, Germany
Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
Center for Neurobehavioral Genetics, University of California, Los Angeles, CA, USA
Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, The Netherlands
Department of Social Sciences, Utrecht University, Utrecht, The Netherlands
Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Padova, Italy
M. Skłodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland
Department of Epidemiology, Institute of Occupational Medicine, Department of Epidemiology, Lodz, Poland
Department of Clinical Nutrition, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
Netherlands Consortium for Healthy Ageing, Leiden University Medical Center, The Netherlands
Department of Nutrition and Dietetics, Harokopio University, Athens, Greece

The Price Foundation Collaborative Group


118Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
119Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA
120Rosenbeck Hospital for Behavioral Medicine, Prien, Germany
121Department of Psychiatry, University of Munich (LMU), Munich, Germany
122New York Presbyterian Hospital, Westchester Division, Weill Medical College of Cornell University, White Plains, NY, USA
123Laureate Psychiatric Clinic and Hospital, Tulsa, OK, USA
124Center for Addiction and Mental Health, Toronto, Canada
125Neuropsychiatric Research Institute, Fargo, ND, USA

126Neuropsychiatric Research Institute, Fargo, ND, USA
127Department of Psychiatry, Toronto General Hospital, University Health Network, Toronto, Canada
128Department of Clinical Molecular Biology, University of Kiel, Kiel, Germany
129Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
130Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-University, Munich, Germany
131CNRS 8090-Institute of Biology, Pasteur Institute, Lille, France
132The Program for Human and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
133Finnish Institute of Occupational Health, Province of Southern Finland, Helsinki, Finland
134NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway
135Department of Psychology, University of Oslo, Oslo, Norway
136Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway
137Kavli Research Centre for Aging and Dementia, Haraldsplass Deaconess Hospital, Bergen, Norway
138K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen, Bergen, Norway
139KG Jebsen Centre for Psychosis Research, Norwegian Centre For Mental Disorders Research (NORMENT), Department of Clinical Science, University of Bergen, Bergen, Norway
140Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
141Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
142Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
143Palacky University, Olomouc, Czech Republic
144University Health Network and Mount Sinai Hospital, Toronto General Hospital, and Samuel Lunenfeld Research Institute, Toronto, ON, Canada
145Departments of Psychiatry, and Genetics and Genomic Sciences, Seaver Autism Center, and the Mindich Child Health and Development Institute, Mount Sinai School of Medicine, New York, NY, USA
146The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada
147Department of Psychiatry and Psychotherapy, Medical University Vienna, Vienna, Austria
148The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
149Rheumatology Unit, Department of Medicine at the Karolinska University Hospital, Solna, Sweden
150Department of Nutrition, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

The Price Foundation Collaborative Group


118Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
119Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA
120Rosenbeck Hospital for Behavioral Medicine, Prien, Germany
121Department of Psychiatry, University of Munich (LMU), Munich, Germany
122New York Presbyterian Hospital, Westchester Division, Weill Medical College of Cornell University, White Plains, NY, USA
123Laureate Psychiatric Clinic and Hospital, Tulsa, OK, USA
124Center for Addiction and Mental Health, Toronto, Canada
125Neuropsychiatric Research Institute, Fargo, ND, USA
127Department of Clinical Neuroscience, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA
128Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
129Neuropsychiatric Research Biotechnologies, University of Pisa, Pisa, Italy
130Eating Disorders Section, Institute of Psychiatry, King's College, University of London, London, England
131Department of Psychology, Florida State University, Tallahassee, FL, USA
132Department of Psychology, Georgia State University, Atlanta, GA, USA
133Center for Health Sciences, SRI International, Menlo Park, CA, USA
134Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
135Department of Psychiatry, University of California at San Diego, San Diego, CA, USA
136Department of Psychiatry, Brain Mind Institute EPFL—Lausanne, Center for Psychiatric Neuroscience, University of Lausanne Medical School, Lausanne, Switzerland